生命科学资讯
生物技术与制药领域的最新动态
雅培股价下跌,全球诊断与营养业务销售下滑拖累盈利。
Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings
百时美施贵宝从卫材挖角顶尖神经科学研究专家。
Chutes & Ladders—BMS snags top neuro researcher from Eisai
J. Craig Venter 启动基因组学初创公司,旨在提升诊断洞察力
J. Craig Venter launches genomics startup designed to boost diagnostic insights
赛诺菲计划全球提交关键湿疹新药申请,尽管三期试验结果喜忧参半
Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout
美国国立卫生研究院全面禁止在研究中使用流产胎儿组织。
NIH imposes full ban of aborted fetal tissue in research
百时美施贵宝与Janux达成8.5亿美元实体瘤T细胞衔接器协议。
BMS pens $850M solid tumor pact with T-cell engager biotech Janux
Corcept凭借三期癌症试验成功反弹,摆脱FDA库欣病药物被拒阴霾。
Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection
Corxel获2.87亿美元D轮融资,推进口服GLP-1减肥药II/III期临床研究
Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
霍斯反击癌症药物皮肤毒性,但股价依旧冻结。
Hoth strikes back against cancer drug skin toxicities, but share price stays frozen
辉瑞CEO将美国疫苗困境归咎于小肯尼迪的“反科学”立场:《华尔街日报》报道
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FDA发布多发性骨髓瘤加速审批中MRD与完全缓解的草案政策指南。
FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma
IO公司考虑在癌症疫苗受挫裁员半数后数月内进一步削减员工。
IO mulls more layoffs months after halving head count in wake of cancer vaccine setback
深入交流:Beam首席执行官谈基因编辑生物科技在体内递送领域的“重大推进”
Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery
癌症影像公司收购Lisata,获得二期实体瘤药物。
Cancer imaging company buys Lisata for phase 2-stage solid tumor drug
诺和诺德剥离糖尿病资产给Aspect,细胞疗法领域战略收缩。
Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
全球临床试验公司Catalyst Clinical加入全球CRO组合。
Worldwide Clinical Trials adds Catalyst Clinical to global CRO mixture
Nkarta首席执行官在摩根大通会议上全粉装扮,此举意义非凡。
Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever
前Spero高管因抗生素疗效声明被美国证监会罚款
Former Spero execs fined by SEC over antibiotic efficacy claims
默克-莫德纳癌症疫苗五年内持续降低黑色素瘤风险49%
Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years